Literature DB >> 35819486

Factors of Early Recurrence After Resection for Intrahepatic Cholangiocarcinoma.

Alexandra Nassar1, Stylianos Tzedakis2, Rémy Sindayigaya2, Christian Hobeika3, Ugo Marchese2, Julie Veziant2, Tatiana Codjia3, Aurélie Beaufrère4, Alix Dhote2, Marie Strigalev2, François Cauchy3, David Fuks2.   

Abstract

BACKGROUND: Two-thirds of patients undergoing liver resection for intrahepatic cholangiocarcinoma experience recurrence after surgery. Our aim was to identify factors associated with early recurrence after resection for intrahepatic cholangiocarcinoma.
METHODS: Patients with intrahepatic cholangiocarcinoma undergoing curative intent resection (complete resection and lymphadenectomy) were included in two centers between 2005 and 2021 and were divided into three groups: early recurrence (< 12 months after resection), delayed recurrence (> 12 months), and no recurrence. Patients experiencing early (< 90 days) postoperative mortality were excluded.
RESULTS: Among 120 included patients, 44 (36.7%) experienced early recurrence, 24 (20.0%) experienced delayed recurrence, and 52 (43.3%) did not experience recurrence after a median follow-up of 59 months (IQR: 26-113). The median recurrence-free survival was 16 months (95% CI: 9.6-22.4). Median overall survival was 55 months (95% CI: 45.7-64.3), while it was 25 months for patients with early recurrence (p < 0.001). Patients with early recurrence had significantly larger tumors (59.1% of tumors > 70 mm in early vs. 58.3% in delayed vs. 26.9% in no recurrence group, p = 0.002), multiple lesions (65.9% vs. 29.2% vs. 11.5%, p < 0.001), and positive lymph nodes (N +) (38.6% vs. 37.5% vs. 11.5%, p = 0.005). In multivariable analysis, presence of multiple lesions (OR: 9.324; 95% CI: 3.051-28.489; p < 0.001) and positive lymph nodes (OR: 3.307. 95% CI: 1.001-11.011. p = 0.05) were associated with early recurrence.
CONCLUSION: Early recurrence after curative resection of intrahepatic cholangiocarcinoma is frequent and is associated with the presence of multiple lesions and positive lymph nodes, raising the question of surgery's futility in this context.
© 2022. The Author(s) under exclusive licence to Société Internationale de Chirurgie.

Entities:  

Mesh:

Year:  2022        PMID: 35819486     DOI: 10.1007/s00268-022-06655-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.282


  2 in total

1.  Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival.

Authors:  Lu Wu; Diamantis I Tsilimigras; Anghela Z Paredes; Rittal Mehta; J Madison Hyer; Katiuscha Merath; Kota Sahara; Fabio Bagante; Eliza W Beal; Feng Shen; Timothy M Pawlik
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

Review 2.  The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: A review.

Authors:  Carlo Sposito; Michele Droz Dit Busset; Matteo Virdis; Davide Citterio; Maria Flores; Marco Bongini; Monica Niger; Vincenzo Mazzaferro
Journal:  Eur J Surg Oncol       Date:  2021-08-10       Impact factor: 4.424

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.